A half-life study, not a cart note
Enter the clock. Annotate which arm was daily and which was PRN. Stamp only the endpoint that arm was powered for.
Seventeen point five hours is not a slogan. Integrated healthy-volunteer work put mean t½ there, with a wide percentile spread, after a single 2.5 to 20 mg swallow.
A 2.5 milligram daily card exists because that long curve accumulates. Steady state arrives around day five, with about 1.6-fold accumulation - math that a four-hour cousin cannot copy.
This study file ignores checkout banners and coupon captions. Those belong to a fill window this Boston desk does not run.
PRN 10 and 20 mg tablets asked a weekend-window question. Daily 2.5 and 5 mg tablets asked whether a low steady level could keep IIEF and, on some arms, urinary scores moving.
Cross-check counseling marks on the Cialis formulary page. This file keeps the pharmacology study, not the bedside checklist.
What the 2.5 daily arms actually asked
Once-daily 2.5, 5, and 10 mg tablets were tested in three early daily studies totaling 853 men across ages, ethnicities, and ED severities.
Successful intercourse attempts on 2.5 mg daily sat near 50 percent in the general-population daily work, against placebo in the low thirties. That is a real lift. It is not a 5 mg twin.
Diabetes-associated ED arms were harder. Successful attempts on 2.5 mg daily sat near 46 percent versus 28 percent on placebo in the labeled daily diabetes study - still a gap, still not a miracle.
Treatment-naive daily work later randomized 217 men to 5 mg versus placebo and saw 68 percent versus 52 percent successful attempts. That paper was a 5 mg question, not a 2.5 mg reprint.
Annotate which daily milligram the paper used before you stamp 'daily tadalafil works.' The locked 2.5 card on this site is context, not a claim that every daily endpoint was won at 2.5.
IPSS moved on 5 mg, not always on 2.5
Men with both ED and BPH-LUTS entered a 12-week Phase 3 daily study of 2.5 or 5 mg versus placebo after a four-week placebo lead-in.
IIEF-EF rose on both 2.5 and 5 mg daily versus placebo. That co-primary did not require the higher daily chip.
IPSS improved significantly on 5 mg from week two through endpoint. The 2.5 mg daily arm did not carry the urinary primary the same way.
McVary's earlier daily work that stepped 5 mg then 20 mg also moved IPSS versus placebo. That ladder is not a 2.5 mg BPH stamp.
US labeling later treated 5 mg daily as the dual ED-plus-BPH card. This desk still locks 2.5 daily as SERP context - a pharmacology start, not a claim that 2.5 owns the prostate score.
PRN arms asked a different clock
On-demand 10 and 20 mg swallows asked whether a man could keep a window open for about a day and a half after one tablet, not whether a trough stayed up all month.
Porst and others built the 36-hour usefulness story on PRN timing, not on a 2.5 mg breakfast habit. Mixing those designs is how a study file turns into a brochure.
SEP diaries and IIEF-EF domains were the usual ED scores. They are not IPSS. A man can gain intercourse success and still fail a urinary primary.
No more than one PRN tablet a day was the safety frame. Stacking a daily 2.5 on a leftover 20 mg from the weekend is not a studied arm.
If you want the short-clock cousin, open the sildenafil discovery file. That page is a miss-then-hit story, not a half-life study.
Every tadalafil paper inherits the nitrate hold
Organic nitrates plus any PDE5 inhibitor can drop blood pressure into a dangerous range. Trial protocols excluded that mix. So does the label.
Forty-eight hours is the usual wait after tadalafil before a nitrate can be considered, longer than the sildenafil clock, because the curve is longer.
Alpha-blocker hypotension is a separate, manageable interaction when both drugs are indicated. It is not a reason to say tadalafil is forbidden in BPH - the 5 mg daily card is labeled for LUTS when used alone.
Riociguat sits on the same hard-stop list as nitrates. I will not soften that because a daily 2.5 tablet looks small.
Stamp the hold on every study summary. A clean IIEF curve does not rescue a nitrate collision.
Seventeen and a half hours on one curve
Mean oral clearance sat near 2.5 L/h in the pooled healthy-subject analysis. Apparent volume hovered around 63 L. Those two numbers produce the long half-life.
Concentrations rose to a mean Cmax near two hours, then fell almost monoexponentially. Food did not shove bioavailability outside the usual 90 percent confidence band.
Elderly men ran a longer mean half-life in some summaries - about 21.6 hours - which is a counseling mark for accumulation, not a reason to invent a new start tablet on this page.
A 36-hour usefulness window is a clinical nickname built on that curve. It is not a second half-life and it is not a promise that every man stays in range for a day and a half.
Dose proportionality held across the studied 2.5 to 20 mg range. Doubling the tablet doubled exposure. That is why daily and PRN cards are different exposures, not different molecules.
This curve is not the sildenafil clock
Sildenafil and vardenafil half-lives sit near four hours. They cannot accumulate into a true once-daily ED tablet the way tadalafil can.
Food hits those shorter tablets harder. Tadalafil's quiet meal effect is a PK finding, not a personality trait.
Back and muscle ache show up more often on the long curve, often blamed on a PDE11 footnote. That is an adverse-event pattern, not an efficacy score.
Adcirca-branded 40 mg daily for pulmonary arterial hypertension is a different exposure and a different trial family. Do not import PAH six-minute-walk numbers into a 2.5 mg ED file.
Comparison detail on the third cousin sits in the Levitra comparison brief. This page stays with tadalafil's own clock.
How we stamp daily versus PRN ink
- T½ ~17.5 h in healthy men; steady state ~day 5; ~1.6× accumulation.
- Daily 2.5 mg: ED intercourse success above placebo; not the dual BPH card.
- Daily 5 mg: the arm that carried IPSS in the combined ED+LUTS Phase 3.
- PRN 10/20 mg: window question, not a trough question.
Write the regimen on the same line as the endpoint. Daily 2.5 / IIEF is one stamp. Daily 5 / IPSS is another. PRN 20 / 36-hour window is a third.
Refuse a sentence that says 'tadalafil works for prostate symptoms' if the only tablet in the room is 2.5 mg daily.
Refuse a sentence that says 'the weekend pill is 2.5 mg.' The weekend nickname grew from PRN timing.
Keep the nitrate hold on every stamp. A pretty accumulation curve does not buy a nitroglycerin exception.
Close the file when the question is 'what should I buy.' That question never entered the PK papers.
Food barely moves tadalafil; CYP3A4 does
High-fat meals did not push tadalafil Cmax or AUC outside the usual bioequivalence-style bounds in the integrated PK work. That is a real difference from the shorter cousins.
CYP3A4 inhibitors raise exposure. Ritonavir and strong azoles are not a 'take with dinner' problem - they are a dose-hold or a stop.
CYP3A4 inducers such as rifampin pull levels down. A daily 2.5 mg tablet cannot out-shout an inducer.
Grapefruit is a weaker, messier CYP3A4 story. I mention it as noise, not as a second half-life.
Alcohol is not a specific PK wrecking ball at modest intake. It is still a hypotension stack if someone is already vasodilated.
What the 2.5 daily study keeps
The long half-life is the reason a daily tablet exists. Without ~17.5 hours, 2.5 mg every morning is just a small PRN tablet taken on the wrong schedule.
Daily 2.5 mg has ED ink. It does not automatically inherit the urinary primary that 5 mg daily carried in the combined BPH study.
Nitrates stay closed. Food stays quiet. CYP3A4 stays loud. That is the pharmacology stamp.
Ask a clinician who can see your nitrate list before anyone changes a tablet. THL-S02 is a study file, not a cart.
Talk with your own clinician or pharmacist before you change a tablet or a dose. Open the ledger disclaimer.
Updated: